Hawkeye Therapeutics
Hawkeye Therapeutics is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Hawkeye Therapeutics.
Hawkeye Therapeutics is a company.
Key people at Hawkeye Therapeutics.
Hawkeye Therapeutics refers to multiple entities across search results, but the most prominent innovative profile is Hawkeye Bio (also referenced as Hawkeye Therapeutics in collaborations), a biotech startup developing early cancer detection technology. It builds LEAP technology, a blood-based test measuring cancer-related enzyme activity in asymptomatic individuals to enable early detection of cancers like lung cancer, when most treatable. The product targets patients and healthcare providers seeking non-invasive, affordable screening, solving the problem of late-stage cancer diagnosis by offering a 100% safe, fast, and low-cost alternative to traditional methods. A separate Hawkeye Therapeutics, Inc. collaborated on pharmaceutical formulations with Arcutis Biotherapeutics, indicating formulation development expertise.[3][4][5]
An older, unrelated entity, Hawkeye Therapeutics L.L.C., is a durable medical equipment supplier (NPI since 2009) providing items like wheelchairs and respirators, with no recent activity noted.[2] This analysis focuses on the biotech entity due to its alignment with tech/biotech investment contexts.
Hawkeye Bio's origins center on its co-founder and CEO, who leads a small team (<25 employees) in Westlake Village, California, including roles like Product Development Scientist and Assay Development Scientist. The idea emerged from developing a differentiated approach to measure cancer enzyme activity for early detection in undiagnosed individuals, addressing a critical gap in oncology.[3][5]
Hawkeye Therapeutics, Inc. gained visibility through a formulation collaboration agreement with Arcutis Biotherapeutics (now Arcutis, Inc.), an early-stage pharma company, focusing on R&D for new pharmaceutical formulations—likely a pivotal moment in its trajectory.[4][6] No specific founding year or detailed founder backgrounds are available, but the company's limited operating history suggests early-stage status.[6]
Hawkeye rides the early cancer detection trend, fueled by advances in liquid biopsies and AI-driven diagnostics, where timing is critical as global cancer cases rise and survival rates plummet post-metastasis. Market forces like demand for non-invasive screening (projected multi-billion market) and post-pandemic health monitoring favor scalable blood tests.[3][5] It influences the ecosystem by democratizing access—potentially reducing healthcare costs and improving outcomes—while competing with players like Grail or Guardant Health, but differentiated by enzyme-focused, cost-effective tech.
Hawkeye Bio is poised for growth with its lung cancer test launch, potentially capturing share in precision oncology amid rising VC interest in diagnostics. Trends like multimodal biomarkers and regulatory fast-tracks (e.g., FDA breakthrough designations) will shape its path, with partnerships like Arcutis signaling scalability.[4][5] Influence may evolve through acquisitions or expansions into multi-cancer panels, amplifying impact in beating cancer through accessible early detection—tying back to its core mission of saving lives affordably. Limited public data suggests monitoring clinical validations and funding rounds for momentum.
Key people at Hawkeye Therapeutics.
